

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Results of the Phase III INNOVATE trial evaluating ibrutinib with rituximab versus rituximab alone for patients with previously untreated or relapsed/refractory Waldenström macroglobulinemia (WM) demonstrated superiority in terms of _____ with the combination.
 - a. Progression-free survival
 - b. Major response
 - c. Overall response
 - d. All of the above
2. Which of the following statements is true regarding the MYD88 L265P mutation in patients with WM?
 - a. It is present in more than 90% of patients with the disease
 - b. It is associated with a higher risk of disease transformation and death than the risk for patients with MYD88 wild type
 - c. Both a and b
3. It is necessary to permanently discontinue ibrutinib therapy for all patients with WM who develop atrial fibrillation while receiving that drug.
 - a. True
 - b. False
4. Criteria for the initiation of treatment for patients with WM include _____.
 - a. Development of symptoms such as significant peripheral neuropathy
 - b. Evidence of cytopenia
 - c. Both a and b
5. Which of the following statements is true about CXCR4 mutations in patients with WM?
 - a. They are present in approximately 30% to 40% of patients with the disease
 - b. Nonsense CXCR4 mutations are associated with a lower risk of symptomatic hyperviscosity
 - c. Therapies targeting these mutations have shown promise in the treatment of WM
 - d. All of the above
 - e. Both a and b
 - f. Both a and c